Skip to main content

Table 4 Risk factors predicting progression-free survival in HCC patients with MVI who received one-shot CDDP plus RT

From: Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

Parameter Univariate analysis Multivariate analysis
p value OR 95% CI p value
Age (≥ 65/ < 65 years) 0.753    
Gender (female/male) 0.269    
Etiology (with viral hepatitis/without viral hepatitis) 0.991    
ECOG-PS (0/ ≥ 1) 0.799    
Albumin (≥ 3.5/ < 3.5 g/dL) 0.838    
Prothrombin consumption test (≥ 70%/ < 70%) 0.619    
Child–Pugh score (≥ 6/5) 0.375    
mALBI grade (≥ 2b/ ≤ 2a) 0.505    
Diameter of main tumor (≥ 70/ < 70 mm) 0.479    
Number of tumors in the liver (≥ 4/ < 4) 0.201    
Relative tumor volume in the liver (≥ 50%/ < 50%) 0.009 2.79 1.247–6.243 0.013
Vp (3/4) 0.949    
Vv (with/without) 0.713    
Extrahepatic spread (with/without) 0.304    
Alpha-fetoprotein (≥ 400/ < 400 ng/mL) 0.135    
Des-γ-carboxy prothrombin (≥ 400/ < 400 mAU/mL) 0.906    
Best response of MVI (CR or PR/SD or PD) 0.132    
  1. Univariate and multivariate analysis of risk factor of overall survival in HCC patients with MVI who received one-shot CDDP chemotherapy via HAI plus RT. HCC hepatocellular carcinoma; MVI macrovascular invasion; CDDP cisplatin; RT radiation therapy; OR odds ratio; CI confidence interval; ECOG-Performance Status Eastern Cooperative Oncology Group Performance Status; ALBI score = log10([total-bilirubin(mg/dL)]*17.1*0.66 − [albumin(g/dL)]*10*0.085; mALBI grade 1: 2a: 2b: 3 = ALBI score ≤  − 2.6: >  − 2.6 to <  − 2.27: ≥  − 2.27 to ≤  − 1.39: >  − 1.39; Vp portal vein invasion; Vv venous invasion; SD stable disease; PD progressive disease; CR complete response; PR partial response; HAI hepatic arterial infusion